Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs. Standard of Care

Pain Practice

Volumn 11, Issue 6, 2011, Pages 540-551

  Kleinman, Nathan L ^a   Sanchez, Robert J ^b   Lynch, Wendy D ^a   Cappelleri, Joseph C ^b   Beren, Ian A ^a   Joshi, Ashish V ^b  

^a Human Capital Management Services   (United States)

^b PFIZER INC   (United States)

Author keywords

Compliance; Employees; Fibromyalgia; Health benefit costs; Pregabalin; Standard of Care

Indexed keywords

AMITRIPTYLINE; DULOXETINE; PREGABALIN; VENLAFAXINE;

ABSENTEEISM; ADULT; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; DEPRESSION; DIZZINESS; EMPLOYEE; FEMALE; FIBROMYALGIA; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE;

EID: 80655127867     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00453.x     Document Type: Article

References (60)

1. Wolfe F. The epidemiology of fibromyalgia. J Musculoskelet Pain. 1993;1:137-148.
2. Wolfe F, Ross K, Anderson J, Russell IJ, Herbert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19-28.
3. Robinson RL, Jones ML. In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother. 2006;7:1-13.
4. De Girolama G. Epidemiology and social costs of low back pain and fibromyalgia. Clin J Pain. 1991;7(Suppl 1):S1-S7.
5. White KP, Harth M. Classification, epidemiology and natural history of fibromyalgia. Curr Pain Headache Rep. 2001;5:320-329.
6. Naranjo A, Ojeda S, Francisco F, Erausquin C, Rua-Figueroa I, Rodriguez-Lozano C. Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability. Ann Rheum Dis. 2002;61:660-661.
7. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
8. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388-2395.
9. Silverman SL, Harnett J, Zlateva G, Mardekian J. Identifying fibromyalgia-associated symptoms and conditions from a clinical perspective: a step toward evaluating healthcare resource utilization in fibromyalgia. Pain Pract. 2010;10:520-529.
10. Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med. 1992;92:363-367.
11. Wolfe F, Clauw DJ, Fitzcharles M, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600-610.
12. Kleinman N, Harnett J, Melkonian A, Lynch W, Kaplan-Machlis B, Silverman SL. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. J Occup Environ Med. 2009 Dec;51:1384-1393.
13. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61:1498-1508.
14. Berger A, Sadosky A, Dukes EM, Edelsberg J, Zlateva G, Oster G. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care. 2010;16:S126-S137.
15. Lachaine J, Beauchemin C, Landry P. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain. 2010;26:284-290.
16. Palacio A, Uribe CL, Li H, et al. Financial and clinical characteristics of fibromyalgia: a case-control comparison. Am J Manag Care. 2010;16:S118-S125.
17. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol. 2003;30:1318-1325.
18. White KP, Speechley M, Harth M, Ostbye T. The London fibromyalgia epidemiology study: direct health care costs of fibromyalgia syndrome in London, Canada. J Rheumatol. 1999;26:885-889.
19. Hughes G, Martinez C, Myon E, Taïeb C, Wessely S. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum. 2006;54:177-183.
20. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol. 2006;12:124-128.
21. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;40:1560-1570.
22. Penrod JR, Bernatsky S, Adam V, Baron M, Dayan N, Dobkin PL. Health service costs and their determinants in women with fibromyalgia. J Rheumatol. 2004;31:1391-1398.
23. White KP, Speechley M, Harth M, Ostbye T. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. Arthritis Rheum. 1999;42:76-83.
24. Wolfe F, Anderson J, Harkness D, et al. Work and disability status of persons with fibromyalgia. A multicenter investigation. J Rheumatol. 1997;24:1171-1178.
25. Al-Allaf AW. Work disability and health system utilization in patients with fibromyalgia syndrome. J Clin Rheumatol. 2007;13:199-201.
26. Waylonis GW, Ronan PG, Gordon C. A profile of fibromyalgia in occupational environments. Am J Phys Med Rehabil. 1994 Apr;73:112-115.
27. Bernard AL, Prince A, Edsall P. Quality of life issues for fibromyalgia patients. Arthritis Care Res. 2000;13:42-50.
28. Bigatti SM, Cronan TA. An examination of the physical health, health care use, and psychological well-being of spouse of people with fibromyalgia syndrome. Health Psychol. 2002;21:157-166.
29. Burckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the Management of Fibromyalgia Syndrome. Pain in Adults and Children. APS Clinical Practice Guideline Series No 4. Glenview, IL: American Pain Society; 2005.
30. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromylagia syndrome. Ann Rheum Dis. 2008;67:536-541.
31. Joshi MN, Joshi R, Jain AP. Effect of amitriptyline vs. physiotherapy in management of fibromyalgia syndrome: what predicts a clinical benefit? J Postgrad Med. 2009;55:185-189.
32. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Poponen P. A randomized, doble-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37:1279-1286.
33. Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37:32-40.
34. Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum. 1995;38:1211-1217.
35. Ginsberg F, Mancaux A, Joos E, Vanhove P, Famaey J. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskelet Pain. 1996;4:37-47.
36. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852-1859.
37. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974-2984.
38. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5-15.
39. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136:432-444.
40. Chappell AS, Bradley LA, Wiltse C, et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008;1:91-102.
41. Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain. 2009;25:365-375.
42. Mease PJ. Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. Am J Med. 2009;122(12 Suppl):S44-S55.
43. Nickerson B. Recent advances in the treatment of pain associated with fibromyalgia. US Pharm. 2009;34:49-55.
44. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics. 1998;39:14-17.
45. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003;37:1561-1565.
46. Briley M. Drugs to treat fibromyalgia - the transatlantic difference. Curr Opin Investig Drugs. 2010;11:16-18.
47. Hauser W, Bernardy K, Üçeyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin - a meta-analysis of randomized controlled trials. Pain. 2009;145:69-81.
48. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 2005;52:1264-1273.
49. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419-431.
50. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502-514.
51. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792-805.
52. Gore M, Sadosky AB, Zlateva G, Clauw DJ. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract. 2009;9:363-374.
53. Zhao Y, Sun P, Watson P, Mitchell B, Swindle R. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2010 [Epub ahead of print].
54. Kosanke J, Bergstralh E. SAS GMATCH Macro. 2004. Available at: (accessed December 30, 2010).
55. Agency for Healthcare Research and Quality. Clinical Classifications Software (CCS) for ICD-9-CM. Available at: (accessed August 19, 2010).
56. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
57. Blough D, Madden C, Hornbrook M. Modeling risk using generalized linear models. J Health Econ. 1999;18:153-171.
58. Gardiner JC. Survival Analysis: Overview of Parametric, Nonparametric and Simeparametric Approaches and New Developments. SAS Global Forum 2010, Statistics and Data Analysis. Available at: (accessed December 30, 2010).
59. The GENMOD Procedure. SAS/STAT 9.2 User's Guide, 2nd ed. Cary, NC: SAS Institute Inc. Available at: (accessed December 30, 2010).
60. Fietta P, Fietta P, Manganelli P. Fibromyalgia and psychiatric disorders. Acta Biomed. 2007;78:88-95.